Literature DB >> 19482300

MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides.

Joseph D Raffetto1, Yaskara V R Barros, Amanda K Wells, Raouf A Khalil.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of varicose veins. We have shown that MMP-2 causes relaxation of venous segments and suggested a role of venous smooth muscle (VSM) hyperpolarization; however, the downstream mechanisms are unclear. We tested whether MMP-2 induced venous relaxation involves inhibition of the Ca(2+) mobilization mechanisms of VSM contraction due to generation of Arg-Gly-Asp (RGD)-containing peptides.
METHODS: Circular segments of inferior vena cava (IVC) were isolated from male Sprague-Dawley rats, suspended between two wires in a tissue bath, and isometric contraction was measured. Contraction data in mg/mg tissue were presented as means +/- SEM.
RESULTS: In IVC incubated in normal Krebs (2.5 mM Ca(2+)), the alpha-adrenergic agonist phenylephrine (Phe, 10(-5) M) caused initial peak (133.2 +/- 17.5) followed by a maintained contraction (73.4 +/- 11.6), that was inhibited by MMP-2 (1 microg/mL) to 32.4 +/- 12.8 in 30 min. The inhibitory effects of MMP-2 were reversible by washing the tissue with Krebs or in the presence of the MMP inhibitors TIMP-1 (1 microg/mL), Ro 28-2653, and BB-94 (10(-6) M), and were not associated with changes in IVC structure, demonstrating specificity. Angiotensin II (AngII, 10(-6) M) caused a monophasic contraction (114.2 +/- 12.2), that was also inhibited by MMP-2 (66.0 +/- 7.4), suggesting a post-receptor effect on the downstream mechanisms of VSM contraction. To test the role of Ca(2+) release from the sarcoplasmic reticulum, IVC was incubated in Ca(2+)-free 2 mM ethylene glycol-bis(2-aminoethyl ether-N,N,N',N'-tetra-acetic acid (EGTA) Krebs with or without MMP-2. In Ca(2+)-free Krebs, caffeine did not cause contraction, suggesting a limited role of the Ca(2+)-induced Ca(2+)-release mechanism, and Phe and AngII caused a small contraction (7.2 +/- 1.7 and 14.9 +/- 2.8) that was slightly increased by MMP-2 (10.4 +/- 3.0 and 33.8 +/- 10.0), suggesting little effect on IP(3)-induced Ca(2+) release. To test the role of Ca(2+) entry through membrane channels, after eliciting a transient Phe contraction in nominally 0 Ca(2+) Krebs, increasing concentrations of CaCl(2) (0.1, 0.3, 0.6, 1, 2.5 mM) were added and the extracellular Ca(2+) concentration [Ca(2+)](e)-contraction relationship was constructed. The [Ca(2+)](e)-contraction relation was reduced in MMP-2 treated IVC, suggesting inhibition of Ca(2+) entry. In IVC treated with MMP-2, the Ca(2+) channel blocker diltiazem (10(-5)M) did not cause any further inhibition of Phe contraction, suggesting that Ca(2+) entry is already inhibited by MMP-2. To test whether MMP-2 actions involve generation of RGD and modulation of integrin receptors, experiments where repeated in IVC segments saturated with RGD (10(-5) M), or pretreated with the alpha(v)beta(3) integrin blocker cyclo(Ala-Arg-Gly-Asp-3-aminomethylbenzoyl) (cyclo-RGD). RGD-peptide caused only small relaxation of Phe contracted IVC (6.4 +/- 3.4%), and addition of MMP-2 to RGD-treated IVC caused further relaxation (69.7 +/- 3.0%). Pretreatment of IVC with cyclo-RGD did not significantly affect MMP-2 induced relaxation (55.0 +/- 5.0%).
CONCLUSIONS: In rat IVC, MMP-2 attenuates [Ca(2+)](e)-dependent VSM contraction without affecting Ca(2+) release from intracellular Ca(2+) stores. MMP-2 induced VSM relaxation may not involve RGD generation or activation of alpha(v)beta(3) integrin receptor. MMP-2 induced inhibition of the Ca(2+) entry mechanism of VSM contraction may play a role in the venous dilation associated with varicose vein formation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19482300      PMCID: PMC2844458          DOI: 10.1016/j.jss.2008.09.022

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  51 in total

1.  Integrin mobilizes intracellular Ca(2+) in renal vascular smooth muscle cells.

Authors:  W L Chan; N H Holstein-Rathlou; K P Yip
Journal:  Am J Physiol Cell Physiol       Date:  2001-03       Impact factor: 4.249

2.  Integrin-binding peptides containing RGD produce coronary arteriolar dilation via cyclooxygenase activation.

Authors:  T W Hein; S H Platts; K R Waitkus-Edwards; L Kuo; S A Mousa; G A Meininger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-12       Impact factor: 4.733

Review 3.  Proteinase-activated receptors.

Authors:  S R Macfarlane; M J Seatter; T Kanke; G D Hunter; R Plevin
Journal:  Pharmacol Rev       Date:  2001-06       Impact factor: 25.468

Review 4.  Matrix metalloproteinases in venous tissue remodeling and varicose vein formation.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Curr Vasc Pharmacol       Date:  2008-07       Impact factor: 2.719

5.  Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex.

Authors:  Kousuke Marutsuka; Kinta Hatakeyama; Yuichiro Sato; Atsushi Yamashita; Akinobu Sumiyoshi; Yujiro Asada
Journal:  Thromb Res       Date:  2002-09-01       Impact factor: 3.944

Review 6.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

7.  Vasomotor effects of arg-gly-asp (RGD) peptides are limited and not related to endothelium-derived hyperpolarizing factor-mediated relaxation in rat mesenteric arteries.

Authors:  E N Bakker; J C Balt; M Pfaffendorf; J A Spaan; E VanBavel
Journal:  Clin Exp Pharmacol Physiol       Date:  2001-11       Impact factor: 2.557

8.  Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13.

Authors:  D L Gillespie; A Patel; B Fileta; A Chang; S Barnes; A Flagg; M Kidwell; J L Villavicencio; N M Rich
Journal:  J Surg Res       Date:  2002-08       Impact factor: 2.192

9.  Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity.

Authors:  Emilio Fiore; Carlo Fusco; Pedro Romero; Ivan Stamenkovic
Journal:  Oncogene       Date:  2002-08-08       Impact factor: 9.867

10.  Chronic venous insufficiency: clinical and duplex correlations. The Edinburgh Vein Study of venous disorders in the general population.

Authors:  C Vaughan Ruckley; Christine J Evans; Paul L Allan; Amanda J Lee; F Gerald R Fowkes
Journal:  J Vasc Surg       Date:  2002-09       Impact factor: 4.268

View more
  27 in total

1.  Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins.

Authors:  Joseph D Raffetto; Xiaoying Qiao; Katie G Beauregard; Raouf A Khalil
Journal:  J Vasc Surg       Date:  2010-04       Impact factor: 4.268

Review 2.  Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.

Authors:  Elisabeth MacColl; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2015-08-28       Impact factor: 4.030

Review 3.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 4.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 5.  Lymphocytes and the adventitial immune response in atherosclerosis.

Authors:  Kirsti A Campbell; Michael J Lipinski; Amanda C Doran; Marcus D Skaflen; Valentin Fuster; Coleen A McNamara
Journal:  Circ Res       Date:  2012-03-16       Impact factor: 17.367

6.  Decreased homodimerization and increased TIMP-1 complexation of uteroplacental and uterine arterial matrix metalloproteinase-9 during hypertension-in-pregnancy.

Authors:  Juanjuan Chen; Zongli Ren; Minglin Zhu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2017-05-12       Impact factor: 5.858

Review 7.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 8.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

9.  Increased vascular and uteroplacental matrix metalloproteinase-1 and -7 levels and collagen type I deposition in hypertension in pregnancy: role of TNF-α.

Authors:  Wei Li; Ning Cui; Marc Q Mazzuca; Karina M Mata; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

10.  Pregnancy-associated adaptations in [Ca2+]i-dependent and Ca2+ sensitization mechanisms of venous contraction: implications in pregnancy-related venous disorders.

Authors:  Yin Xia; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-03       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.